Isthmus Partners LLC Buys 1,000 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Isthmus Partners LLC grew its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,227 shares of the medical research company’s stock after purchasing an additional 1,000 shares during the quarter. Isthmus Partners LLC’s holdings in Exact Sciences were worth $687,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in EXAS. Huntington National Bank increased its holdings in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in Exact Sciences during the third quarter worth about $34,000. Capital Performance Advisors LLP purchased a new stake in Exact Sciences during the third quarter valued at about $35,000. Asset Planning Inc purchased a new position in shares of Exact Sciences in the fourth quarter valued at about $40,000. Finally, Modus Advisors LLC purchased a new stake in shares of Exact Sciences in the 4th quarter worth about $43,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $47.06 on Monday. The business’s 50 day simple moving average is $52.88 and its 200-day simple moving average is $59.35. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of -8.45 and a beta of 1.25. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities analysts forecast that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EXAS has been the topic of several recent analyst reports. BTIG Research increased their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Piper Sandler cut their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Barclays lowered their price target on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Benchmark reissued a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. Finally, William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.94.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.